EP

EDU

CHRS

Guidelines

2019 CCS/CHRS POSITION STATEMENT ON THE MANAGEMENT OF VENTRICULAR TACHYCARDIA AND FIBRILLATION IN PATIENTS WITH STRUCTURAL HEART DISEASE

Chair(s)

• Eugene C.

  Eugene Crystal

  Cardiology
• 

  Jacqueline Joza, MD

  Assistant Professor of Medicine, Cardiac electrophysiology
  McGill University Health Centre
  McGill University Health Centre

Presenter(s)

• 

  Marc Deyell, MD

  Associate Professor
  University of British Columbia
  University of British Columbia
• John S.

  John Sapp

  Cardiac Electrophysiologist
  Dalhousie University

This session will review the Canadian Cardiovascular Society Position Statement recommendations for the management of ventricular tachycardia and ventricular fibrillation in patients with structural heart disease.

Learning Objectives

At the conclusion of this session, participants will be able to:

• understand the importance of a comprehensive initial investigation for patients with VT/VF and which diagnostic tests are appropriate;
• initiate appropriate acute therapy for VT/VF;
• understand the indications for initiating chronic suppressive therapy for VT/VF in structural heart disease;
• understand the pharmacologic, intervention and device management of patients with VT/VF in structural heart disease;
• recognize alternative therapies for patients with refractory VT/VF; and
• recognize the psychosocial impacts of VT/VF.